-
1
Should the Food and Drug Administration Limit Placebo-Controlled Trials?
Published 2022-07-01Subjects: “…Food and Drug Administration…”
Get full text
Article -
2
A Machine Learning Algorithm to Predict Medical Device Recall by the Food and Drug Administration
Published 2024-11-01“…While the United States Food and Drug Administration (FDA) employs an adverse event reporting program (MedWatch) and database (MAUDE), other data sources and methods might have utility to identify potentially dangerous medical devices. …”
Get full text
Article -
3
Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database
Published 2025-01-01“…In particular, the hepatotoxicity associated with statins use has become one of the clinical concerns that require sufficient attention.MethodsIn this study, we conducted a comprehensive and detailed analysis of the hepatotoxicity of statins based on the data of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter (Q1) of 2004 to the Q1 of 2024 and used Reporting Odds Ratios and Empirical Bayes Geometric Mean to mine the signal of adverse events.ResultsIn this study, hepatic disorder related seven statins all exhibited positive signals. …”
Get full text
Article -
4
Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
Published 2022-07-01“…Objective To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether multiple uses of expedited programmes, and the combinations of expedited programmes with orphan designation, were relevant to different safety profiles.Design Cohort study.Setting USA.Participants All new drugs approved by the FDA between 1 January 2007 and 31 December 2017, followed up until 10 April 2021.Outcome measures Safety events included safety-related withdrawal, new boxed warning, drug safety communication, postapproval risk evaluation mitigation strategy and safety-related labelling changes. …”
Get full text
Article -
5
Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system
Published 2025-01-01“…This study aims to conduct an exploratory analysis of the United States Food and Drug Administration adverse event reporting system (FAERS) database to identify previously unknown drugs that can cause EP and supplement the available evidence for known culprit drugs. …”
Get full text
Article -
6
-
7
-
8
Proton pump inhibitor leaflets: Is there information on deprescribing?
Published 2025-01-01Subjects: Get full text
Article -
9
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine
Published 2025-01-01Get full text
Article -
10
-
11
-
12
Acute pain pathways: protocol for a prospective cohort study
Published 2022-07-01Get full text
Article -
13
-
14
Anesthetic-Induced Oxidative Stress and Potential Protection
Published 2010-01-01Get full text
Article -
15
-
16
-
17
-
18
Delineating Molecular Mechanisms of Squamous Tissue Homeostasis and Neoplasia: Focus on p63
Published 2013-01-01Get full text
Article -
19
<i>Salmonella enterica</i> serovar Schwarzengrund: Distribution, Virulence, and Antimicrobial Resistance
Published 2025-01-01Get full text
Article -
20